How many 8-K filings has Mereo Biopharma Group PLC filed?

Mereo Biopharma Group PLC (MREO) has 14 8-K (Current Event Report) filings on record, spanning Jan 2024 to Mar 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Mereo Biopharma Group PLC 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Mereo Biopharma Group PLC 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Mereo Biopharma Group PLC (MREO) — 8-K Filings

All 8-K filings from Mereo Biopharma Group PLC. Browse 14 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (14)

8-K Filing — Mar 27, 2026
8-K Filing — Dec 29, 2025
Mereo BioPharma Files 8-K on Operations and Financials — Aug 12, 2025 Risk: low
Mereo BioPharma Group plc filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as filing financial statement
Ultragenyx to Acquire Mereo BioPharma for $1 Billion — Jul 10, 2025 Risk: medium
Mereo BioPharma Group plc announced on July 9, 2025, that it has entered into a definitive agreement to be acquired by Ultragenyx Pharmaceutical Inc. for approx
Mereo BioPharma Files 8-K on Shareholder Votes & Exhibits — May 14, 2025 Risk: low
Mereo BioPharma Group plc filed an 8-K on May 13, 2025, reporting on the submission of matters to a vote of security holders and financial statements and exhibi
Mereo BioPharma Files 8-K — Jan 13, 2025 Risk: low
Mereo BioPharma Group plc filed an 8-K on January 13, 2025, reporting events as of January 12, 2025. The filing primarily concerns Regulation FD disclosures and
Mereo BioPharma Files 8-K on Financials — Aug 13, 2024 Risk: low
Mereo BioPharma Group plc filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
Mereo BioPharma Enters Material Definitive Agreement — Jun 14, 2024 Risk: medium
On June 14, 2024, Mereo BioPharma Group plc entered into a material definitive agreement. The filing does not provide specific details on the agreement, the cou
Mereo BioPharma to be Acquired by Acelyrin for $150M — Jun 12, 2024 Risk: medium
Mereo BioPharma Group plc announced on June 11, 2024, that it has entered into a definitive agreement to be acquired by Acelyrin, Inc. for approximately $150 mi
Mereo BioPharma Files 8-K on Shareholder Votes & Financials — May 23, 2024 Risk: low
Mereo BioPharma Group plc filed an 8-K on May 23, 2024, to report on matters submitted to a vote of security holders and financial statements. The filing detail
Mereo BioPharma Files 8-K on Financials — May 15, 2024 Risk: low
Mereo BioPharma Group plc filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
Mereo BioPharma Group plc Files 8-K for Material Agreement — Apr 15, 2024 Risk: medium
On April 15, 2024, Mereo BioPharma Group plc entered into a material definitive agreement. The company, incorporated in England and Wales with its principal exe
Mereo BioPharma Files 8-K on Operations and Financials — Mar 27, 2024 Risk: low
Mereo BioPharma Group plc filed an 8-K on March 27, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
Mereo BioPharma Confirms ADS Registration Under Exchange Act — Jan 8, 2024
Mereo BioPharma Group plc filed an 8-K on January 8, 2024, to disclose that its American Depositary Shares (ADSs), each representing five ordinary shares with a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX